ClinicalTrials.gg
RecruitingNCT07050498ERVANUpdated Jul 3, 2025

Evaluation of the Effects of Virtual Reality on Preoperative Anxiety in Refractive Surgery

An interventional study of Virtual reality and Usual Care Group in Refractive Disorders, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Sep 2024, registered Jun 2025).
  • Started Sep 2024; still recruiting 2 years 1 month later.
Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this study is to determine to what extent the use of a software application prior to refractive surgery involving multisensory immersion (visual and auditory) in a hypnotic and relaxing sound and visual environment can reduce anxiety levels.

The assessment of preoperative anxiety levels will be based on the administration of a psychometric scale (APAIS scale) and the measurement of salivary cortisol, which is a sensitive marker of the patient's stress level.

Read the detailed description

This is a prospective, randomized, open-label, single-center study conducted on two parallel groups of patients undergoing refractive surgery (virtual reality preoperative conditioning or routine preoperative procedure). Therapeutic benefit is based on the assessment of preoperative anxiety using the APAIS scale.

02

Conditions studied

  • Refractive Disorders

Browse trials for

Keywords

  • refractive surgery
03

In context

Refractive Errors

420 studies on the registry are indexed under Refractive Errors; 59 are open to participants now.

This study's planned enrollment of 68 is below the median of 76 across 301 interventional studies indexed under Refractive Errors.

Browse Refractive Errors studies →

Lead sponsor

GCS Ramsay Santé pour l'Enseignement et la Recherche is the lead sponsor of 207 studies on the registry; 99 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient aged 18 years or older,
  • Patient who has read and signed the consent form for participation in the study after a reflection period (between 10 and 45 minutes)
  • Patient who is a candidate for refractive surgery

Exclusion criteria

Exclusion Criteria:

  • to virtual reality (uncontrolled epilepsy, hearing impairment)
  • Pregnant or breastfeeding patient
  • Cushing's disease, Addison's disease, hypo- or hyperthyroidism
  • Patient treated with topical or systemic
  • Patient treated with neuroleptics, anxiolytics, or antidepressants
  • Patient under legal protection, guardianship, or curatorship
  • Patient participating in another blinded research study
  • Patient not affiliated with the French social security system
  • Patient unable to understand the information provided and/or give written : dementia, psychosis, impaired consciousness, non-French-speaking patient
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Virtual reality

    Preoperative conditioning by virtual reality + Routine preoperative procedure (local anesthesia)

    Device: Virtual reality

  • Active comparator
    Usual care

    Routine preoperative procedure (local anesthesia)

    Procedure: Usual Care Group

Interventions

  • DeviceVirtual reality

    Virtual reality hypnosis software applications are Class I medical devices according to Rule 12 of Directive 93/42/EC. They allow, through a virtual reality headset and headphones, to immerse the patient in a hypnotic sound and visual environment. Several visual scenarios can be proposed, allowing the patient to virtually travel to a beach, the seabed, on an alpine walk, etc.). The HypnoVR Biofeedback virtual reality device is provided by the HypnoVR company.

  • ProcedureUsual Care Group

    Routine preoperative procedure (local anesthesia)

06

What researchers measure

Primary outcomes

  1. Preoperative anxiety level

    The preoperative anxiety level is measured on the APAIS scale. The APAIS scale is a self-assessment consisting of six questions with expected responses rated from 1 (the patient strongly disagrees with the statement) to 5 (the patient strongly agrees with the statement) out of a minimum overall score of 6 and a maximum overall score of 30. The first three questions relate to anesthesia, and the next three relate to surgery. Of the three questions (related to anesthesia or surgery), two assess preoperative anxiety, and the third assesses the need for information. The APAIS scale calculates four scores: overall anxiety, surgery-related anxiety, anesthesia-related anxiety, and information need. A total anxiety score of 11 or higher corresponds to a high level of anxiety.

    Time frame: Preoperative procedure

Secondary outcomes

  1. Intraoperative pain intensity

    Pain intensity will be assessed using a simple numerical rating scale (SNR) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: Immediately after surgery

  2. Postoperative pain intensity

    Pain intensity will be assessed using a simple numerical rating scale (SNR) ranging from 0 (no pain) to 10 (worst imaginable pain).

    Time frame: 15 minutes after the End of surgery

  3. Intraoperative comfort

    Comfort will be assessed using a simple numerical rating scale (SNR) ranging from 0 (minimum comfort) to 10 (maximum comfort).

    Time frame: 15 minutes after the End surgery

  4. Postoperative Overall Patient Satisfaction

    Overall Patient Satisfaction will be assessed using a simple numerical rating scale (SNR) ranging from 0 (not at all satisfied) to 10 (very satisfied).

    Time frame: 15 minutes after the End of surgery

  5. Change in salivary cortisol

    After rinsing the mouth with water, a 1 ml sample of salivary secretions without stimulation will be taken using a Salivette® (Sarstedt TM). The samples will be stored at -20°C before being analyzed by the private laboratory Eurofins, using an ELISA test (analytical sensitivity = 1.38 nmol/L; functional sensitivity = 8.28 nmol/L; upper detection limit \~110 nmol/L).

    Time frame: Before any study procedure

  6. Change in salivary cortisol

    After rinsing the mouth with water, a 1 ml sample of salivary secretions without stimulation will be taken using a Salivette® (Sarstedt TM). The samples will be stored at -20°C before being analyzed by the private laboratory Eurofins, using an ELISA test (analytical sensitivity = 1.38 nmol/L; functional sensitivity = 8.28 nmol/L; upper detection limit \~110 nmol/L).

    Time frame: Just before surgery

  7. Change in salivary cortisol

    After rinsing the mouth with water, a 1 ml sample of salivary secretions without stimulation will be taken using a Salivette® (Sarstedt TM). The samples will be stored at -20°C before being analyzed by the private laboratory Eurofins, using an ELISA test (analytical sensitivity = 1.38 nmol/L; functional sensitivity = 8.28 nmol/L; upper detection limit \~110 nmol/L).

    Time frame: 15 minutes after the end of surgery

  8. Heart rate

    Heart rate measurement in both groups

    Time frame: Before any study procedure

  9. Blood pressure

    Blood pressure measurement in both groups

    Time frame: Before any study procedure

  10. Heart rate

    Heart rate measurement in both groups

    Time frame: Before surgery

  11. Blood pressure

    Blood pressure measurement in both groups

    Time frame: Before surgery

  12. Heart rate

    Heart rate measurement in both groups

    Time frame: 15 minutes after the end of surgery

  13. Blood pressure

    Blood pressure measurement in both groups

    Time frame: 15 minutes after the end of surgery

  14. Tolerance

    The tolerance of the test procedure will be assessed by collecting adverse events occurring during the duration of the study.

    Time frame: 15 minutes after the end of surgery

07

Study locations

1 of 1 sites recruiting
  • Clinique Monticelli
    Marseille, 13008, France
    Recruiting
    • Louis HOFFART, MD · Contactlouis.hoffart@me.com · 04 91 16 22 22
    • Louis HOFFART, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07050498
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Sep 18, 2024
Primary completion
Sep 18, 2026 (estimated)
Completion
Sep 18, 2026 (estimated)
Last update
Jul 3, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion